Blog
RSS FeedPosted by Michael Wonder on 17 Sep 2017
Multivariate and network meta-analysis of multiple outcomes and multiple treatments: rationale, concepts, and examples
13 September 2017 - Organisations such as the NICE require the synthesis of evidence from existing studies to inform their decisions—for ...
Posted by Michael Wonder on 12 Sep 2017
War on drugs: big pharma fights NHS bill curbs
10 September 2017 - With NHS budgets under pressure and medicine prices inexorably going up, something had to give. ...
Posted by Michael Wonder on 11 Sep 2017
NICE: We're the institute of 'yes'
11 September 2017 - But Meindert Boysen says affordability conversations with pharma need to happen earlier. ...
Posted by Michael Wonder on 06 Sep 2017
NICE publishes updated guidance on the use of Nexavar on the NHS
6 September 2017 - NICE has updated its 2010 guidance on the use of sorafenib tosylate (Nexavar) on the NHS ...
Posted by Michael Wonder on 05 Sep 2017
NICE publishes second draft guidance for ixazomib citrate
5 September 2017 - The Department of Health has asked NICE to produce guidance on use of ixazomib citrate (Ninlaro) in ...
Posted by Michael Wonder on 04 Sep 2017
Merck’s Erbitux backed by NICE for head and neck cancer
4 September 2017 - Merck’s Erbitux is being recommended for routine NHS use to treat recurrent or metastatic squamous cell ...
Posted by Michael Wonder on 04 Sep 2017
US biotech Kite set to be first to launch one-time cancer gene therapy in Britain
3 September 2017 - US biotech Kite is expected to be first out of the blocks in Britain to launch ...
Posted by Michael Wonder on 01 Sep 2017
NICE says benefits of breast cancer drug fulvestrant too uncertain to make it cost effective
1 September 2017 - NICE has published draft guidance saying the evidence on using fulvestrant to treat a type of breast ...
Posted by Michael Wonder on 31 Aug 2017
Final NHS green light for Allergan’s IBS-D drug
31 August 2017 - Allergan’s Truberzi has become the first treatment for irritable bowel syndrome with diarrhoea to be reviewed ...
Posted by Michael Wonder on 28 Aug 2017
How to design the cost-effectiveness appraisal process of new health care technologies to maximise population health: a conceptual framework
22 August 2017 - This paper presents a conceptual framework to analyse the design of the cost-effectiveness appraisal process of new ...
Posted by Michael Wonder on 28 Aug 2017
NICE terminates appraisal of another cancer medicine
23 August 2017 - NICE has terminated its appraisal of idelalisib with ofatumumab acetate for the treatment of patients with ...
Posted by Michael Wonder on 28 Aug 2017
Europe’s first stem cell therapy backed by NICE
25 August 2017 - Chiesi's Holoclar, the first stem-cell therapy to be cleared by European regulators, has received a green ...
Posted by Michael Wonder on 27 Aug 2017
Breast cancer drug Perjeta at risk in price wrangle
27 August 2017 - Thousands of women with advanced breast cancer could be denied a drug therapy that can extend ...
Posted by Michael Wonder on 27 Aug 2017
NICE reverses stance on Takeda’s Adcetris
25 August 2017 - NICE reverses stance on Takeda’s Adcetris. ...
Posted by Michael Wonder on 23 Aug 2017
NICE rejects thyroid cancer drugs
23 August 2017 - It is looking likely that patients in England will loose NHS access to Ipsen’s Cometriq and ...